glp-1 drug companies 3 Stock Picks: LLY, VKTX, and GPCR GLP-1 Agonists Weight Loss Drugs

To date, these GLP-1 drugs have been approved to treat three adult populations: individuals with type 2 diabetes, individuals with a body mass index (BMI) of 30 or greater (obesity), and individuals with a BMI between 27 and 30 (overweight) with at least one weight-related health condition, such as cardiovascular disease, high blood pressure, high cholesterol, prior stroke, prior heart attack, and chest pain (angina)

doi: 10.1016/S0140-6736(87)91194-9

Successful differentiation into IPC has been reported using hMSC derived from various tissues, including adipose tissue [35, 36, 43,44,45], umbilical cord [46,47,48], Whartons jelly [37, 49, 50] and bone marrow [51]

Acta Endocrinol (Buchar)

[DOI] [PubMed] [Google Scholar] 10.Nauck M.A., Heimesaat M.M., Behle K., Holst J.J., Nauck M.S., Ritzel R

doi: 10.1016/S0140-6736(14)60976-4 [DOI] [PubMed] [Google Scholar] 92.Sorli C, Harashima SI, Tsoukas GM, et al